Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_assertion type Assertion NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_head.
- NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_assertion description "[This phase 2 trial (ClinicalTrials.gov identifier NCT00548093) assessed the efficacy, safety, and impact on health-related quality of life of dacomitinib (PF-00299804), an irreversible tyrosine kinase inhibitor (TKI) of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, in patients with KRAS wild-type non-small cell lung cancer (NSCLC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_provenance.
- NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_assertion evidence source_evidence_literature NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_provenance.
- NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_assertion SIO_000772 24501009 NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_provenance.
- NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_assertion wasDerivedFrom befree-2016 NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_provenance.
- NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_assertion wasGeneratedBy ECO_0000203 NP1152596.RANf2z9WTNK_igfRBZWI2EDkUGAO5OFLyjhMzPcaz2PNM130_provenance.